Management and outcome of CSF-JC virus PCR-negative PML in a natalizumabtreated patient with MS

Neurology

Volumn 77, Issue 23, 2011, Pages 2010-2016

  Kuhle, J ^a   GosertR , ^a   Buhler R ^a   Derfuss, T ^a   Sutter, R ^a   Yaldizli, O ^a   Radue, E W ^a   Ryschkewitsch, C ^a   Major, E O ^a   Kappos, L ^a   Frank, S ^a   Hirsch, H H ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; METHYLPREDNISOLONE; NATALIZUMAB; VIRUS DNA;

ADULT; ARTICLE; BRAIN BIOPSY; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; DRUG WITHDRAWAL; FEMALE; HEMIPARESIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOHISTOCHEMISTRY; MULTIPLE SCLEROSIS; PLASMAPHERESIS; POLYMERASE CHAIN REACTION; POLYOMA VIRUS; POLYOMA VIRUS CV; POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; TREATMENT DURATION;

EID: 82955175412     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31823b9b27     Document Type: Article

References (29)

1. Berger JR, Kaszovitz B, Post MJ, Dickinson G. Progressivemultifocal leukoencephalopathy associated with humanimmunodeficiency virus infection: A review of the literaturewith a report of sixteen cases. Ann Intern Med 1987;107:78-87. (Pubitemid 17098643)
2. Khanna N, Elzi L, Mueller NJ, et al. Incidence and outcomeof progressive multifocal leukoencephalopathy over20 years of the Swiss HIV Cohort Study. Clin Infect Dis2009;48:1459-1466.
3. Koralnik IJ. Progressive multifocal leukoencephalopathyrevisited: Has the disease outgrown its name? Ann Neurol2006;60:162-173. (Pubitemid 44182391)
4. Gosert R, Kardas P, Major EO, Hirsch HH. RearrangedJC virus noncoding control regions found in progressivemultifocal leukoencephalopathy patient samples increasevirus early gene expression and replication rate. J Virol2010;84:10448-10456.
5. Khanna N, Wolbers M, Mueller NJ, et al. JC virus-specificimmune responses in human immunodeficiency virus type1 patients with progressive multifocal leukoencephalopathy.J Virol 2009;83:4404-4411.
6. Du Pasquier RA, Schmitz JE, Jean-Jacques J, et al. Detectionof JC virus-specific cytotoxic T lymphocytes inhealthy individuals. J Virol 2004;78:10206-10210. (Pubitemid 39187140)
7. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumabplus interferon beta-1a for relapsing multiple sclerosis.N Engl J Med 2006;354:911-923.
8. Polman CH, O'Connor PW, Havrdova E, et al. A randomized,placebo- controlled trial of natalizumab forrelapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
9. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluationof patients treated with natalizumab for progressive multifocalleukoencephalopathy. N Engl J Med 2006;354:924-933.
10. Kappos L, Bates D, Hartung HP, et al. Natalizumab treatmentfor multiple sclerosis: Recommendations for patientselection and monitoring. Lancet Neurol 2007;6:431-441. (Pubitemid 46551850)
11. Cinque P, Dumoulin A, Hirsch HH. Diagnosis of polyomavirusinfection, replication and disease. In: Jerome K,ed. Laboratory Diagnosis of Viral Infections. Zug, Switzerland:Informa; 2009;401-424.
12. Ryschkewitsch C, Jensen P, Hou J, Fahle G, Fischer S,Major EO. Comparison of PCR-southern hybridizationand quantitative real-time PCR for the detection of JC andBK viral nucleotide sequences in urine and cerebrospinalfluid. J Virol Methods 2004;121:217-221. (Pubitemid 39295712)
13. Dumoulin A, Hirsch HH. Re-evaluating and optimizingpolyomavirus BK and JC real-time PCR assays to raresequence polymorphisms. J Clin Microbiol Epub 2011Feb 16.
14. Reiber H, Lange P. Quantification of virus-specific antibodiesin cerebrospinal fluid and serum: Sensitive and specificdetection of antibody synthesis in brain. Clin Chem1991;37:1153-1160. (Pubitemid 21925939)
15. Cinque P, Koralnik IJ, Clifford DB. The evolving face ofhuman immunodeficiency virus-related progressive multifocalleukoencephalopathy: Defining a consensus terminology.J Neurovirol 2003;9(suppl 1):88-92. (Pubitemid 36656477)
16. Hirsch HH, Meylan PR, Zimmerli W, Iten A, BattegayM, Erb P. HIV-1-infected patients with focal neurologicsigns: Diagnostic role of PCR for Toxoplasma gondii, Epstein-Barr virus, and JC virus. Clin Microbiol Infect1998;4:577-584. (Pubitemid 28498022)
17. Safdar A, Rubocki RJ, Horvath JA, Narayan KK, WaldronRL. Fatal immune restoration disease in human immunodeficiencyvirus type 1-infected patients with progressivemultifocal leukoencephalopathy: Impact of antiretroviraltherapy- associated immune reconstitution. Clin Infect Dis2002;35:1250-1257. (Pubitemid 35305874)
18. Agostini HT, Ryschkewitsch CF, Mory R, Singer EJ, StonerGL. JC virus (JCV) genotypes in brain tissue from patientswith progressive multifocal leukoencephalopathy (PML) andin urine from controls without PML: Increased frequency ofJCV type 2 in PML. J Infect Dis 1997;176:1-8. (Pubitemid 27272845)
19. Sugimoto C, Ito D, Tanaka K, et al. Amplification of JCvirus regulatory DNA sequences from cerebrospinal fluid:diagnostic value for progressive multifocal leukoencephalopathy.Arch Virol 1998;143:249-262. (Pubitemid 28146989)
20. Weber T, Trebst C, Frye S, et al. Analysis of the systemic andintrathecal humoral immune response in progressive multifocalleukoencephalopathy. J Infect Dis 1997;176:250-254. (Pubitemid 27272877)
21. Berner B, Krieter DH, Rumpf KW, et al. Progressive multifocalleukoencephalopathy in a renal transplant patientdiagnosed by JCV-specific DNA amplification and an intrathecalhumoral immune response to recombinant virusprotein 1. Nephrol Dial Transplant 1999;14:462-465. (Pubitemid 29062817)
22. Giudici B, Vaz B, Bossolasco S, et al. Highly activeantiretroviral therapy and progressive multifocal leukoencephalopathy:effects on cerebrospinal fluid markersof JC virus replication and immune response. Clin InfectDis 2000;30:95-99. (Pubitemid 30067068)
23. Ryschkewitsch CF, Jensen PN, Monaco MC, Major EO.JC virus persistence following progressive multifocal leukoencephalopathyin multiple sclerosis patients treatedwith natalizumab. Ann Neurol 2010;68:384-391.
24. Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immunereconstitution in HIV-infected patients. Clin Infect Dis2004;38:1159-1166.
25. Clifford DB, De LA, Simpson DM, Arendt G, GiovannoniG, Nath A. Natalizumab-associated progressive multifocalleukoencephalopathy in patients with multiplesclerosis: Lessons from 28 cases. Lancet Neurol 2010;9:438-446.
26. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathyand other disorders caused by JC virus: Clinicalfeatures and pathogenesis. Lancet Neurol 2010;9:425-437.
27. Delbue S, Marchioni E, Sotgiu G, et al. Longitudinalstudy of two cases of progressive multifocal leukoencephalopathywith a clinical benign evolution. J Neurovirol2007;13:268-273. (Pubitemid 47050653)
28. Clifford DB, Yiannoutsos C, Glicksman M, et al. HAARTimproves prognosis in HIV-associated progressive multifocalleukoencephalopathy. Neurology 1999;52:623-625. (Pubitemid 29075615)
29. Stangel M, Gold R. [Administration of intravenous immunoglobulinsin neurology: An evidence-based consensus:update 2010.] Nervenarzt Epub 2010 Jun 26.